Dr. Reddy’s Laboratories (NYSE: RDY) has initiated dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia.

From ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE